Oxford Finance and its healthcare real estate group closed a company record level of originations in 2022, with Oxford providing more than $867 million of capital commitments. The group closed a total of 14 transactions, with credit facilities ranging from $9 million to over $124 million.
Oxford Finance, a specialty finance firm focused on healthcare services and life sciences companies worldwide, closed a $115 million senior credit facility to Pearl Street Dental Partners, a dental platform owned by SkyKnight Capital, dentists and management.
ALX Oncology, a clinical-stage immuno-oncology company, entered into a loan facility agreement with Oxford Finance and Silicon Valley Bank for up to $100 million of non-dilutive financing.
Oxford Finance, a specialty finance firm providing senior debt to healthcare services and life sciences companies worldwide, closed a $124.75 million senior credit facility for the acquisition of four Autumn Lake Healthcare skilled nursing facilities located in Maryland containing 520 licensed beds.
Verona Pharma entered into a debt financing facility providing the company with access to up to $150 million from Oxford Finance. The $150 million debt facility replaces the existing $30 million facility with Silicon Valley Bank.
Greenbrook TMS closed its acquisition of Check Five, a Delaware limited liability company. In addition, Greenbrook entered into a credit agreement for a $75 million secured credit facility with Madryn Asset Management and its affiliated entities.
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy for all stages of cancer, closed a $125 million debt facility with Oxford Financial, of which $55 million is available immediately to repay the company’s existing $50 million of debt.
Oxford Finance closed a $30 million senior secured term loan with Selux Diagnostic, a Boston-based medical device company focused on personalized diagnostics to combat superbug infections and fight antibiotic resistance.
Silk Road Medical, a company focused on reducing the risk of stroke, entered into a five-year loan arrangement with Oxford Finance comprising up to a $200 million term loan and up to a $50 million revolving line of credit.
Pliant Therapeutics, a clinical stage biotechnology company, entered into a loan facility agreement with Oxford Finance for up to $100 million of non-dilutive financing.